芪防膝痹方治疗老年性膝骨关节病的疗效研究

目的 观察芪防膝痹方治疗膝骨关节病的临床疗效.方法 将96例患者按随机原则分为治疗组48例、对照组48例.治疗组BID口服芪防膝痹方水煎剂150 mL,对照组QD口服塞来昔布胶囊200 mg.治疗4w后,分别以Lequesne M的膝骨关节病临床评估指数打分表对治疗前后病情严重程度打分,并进行统计分析.结果 治疗组和对照组在疗效上差异无统计学意义（P＞0.05）,治疗组LequesneM表中的各项目评分与对照组差异无统计学意义（P＞0.05）.芪防膝痹方对气滞血瘀型、肝肾不足型的疗效优于风寒湿型[（89.40±9.23）vs （80.20±13.62）,P＜0.05];[（88.70±6.26）vs （80.20±13.62）,P＜0.05],对临床中期患者的效果优于早、晚期[（92.57±2.59） vs （84.63±8.01）,P＜0.05];[（92.57±2.59）vs （83.00±13.51）,P＜0.05],对X线Ⅱ期患者的效果优于Ⅰ、Ⅲ期[（92.75±2.49）vs（84.63±8.01）,P＜0.05];[（92.75±2.49）vs （81.63±13.73）,P＜0.05].结论 芪防膝痹方在临床疗效上与塞来昔布相当,在某些期或某些功能的改善上优于塞来昔布,适合临床推广.

Study on effect of Qi-Fang-Xi-Bi-Decoction in the treatment of knee osteoarthritis

Objective To observe the clinical curative effect and evaluation of the Qi-Fang-Xi-Bi -Decoction （QFXBD） treatment for Knee Osteoarthritis （KOA）. Methods 96 cases of patients randomly divided into treatment group （48 cases, therapy with QFXBD） and control group （48 cases, therapy with celecoxib）. They were scored using Lequesne M of knee osteoarthritis clinical evaluation index table of illness severity and received statistical analysis. Results In the two groups, the therapeutic effects were roughly the same （P〉0.05）. Each item of Lequesne M table in the QFXBG scored the same as that in the celecoxib group （P〉0.05）. Qi anti knee weakness of qi stagnation and blood stasis, liver and kidney deficiency type curative effect was better than that of wind cold dampness syndrome [（ 89.40±9.23 ） vs （80.20±13.62）, P〈0.05]; [（88.70±6.26） vs （80.20±13.62）, P〈0.05]. For QFXBD, mid phase effect was better than early and late phase [（92.57±2.59） vs （84.63±8.01）, P〈0.05]; [（92.57±2.59） vs （83.00±13.51）, P〈0.051. Also patients with X-ray period II were better than those in I, III period [（92.75±2.49） vs （84.63±8.01）, P〈0.05]; [（92.75±2.49） vs （81.63±3.73）, P〈0.05]. Conclusion QFXBD on the clinical efficacy was the same as that in celecoxib group. QFXBD group＇s improvements in certain period or some function were better than those of celecoxib. QFXBG was suitable for clinical promotion.